All lobbying filings

AVENUE SOLUTIONS

Lobbying for AMGEN, INC. · Biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 4

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
S 5459
Biosimilars Access and Affordability Act

Lobbying activity 1

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.